Sun Pharma, India’s largest pharmaceutical company by revenue, announced that it has launched its new anti-hair loss medication, Leqselvi (deuruxolitinib), as an 8 mg oral tablet in the U.S. market following the resolution of a patent dispute with Incyte Corporation.
Leqselvi is designed for the treatment of severe cases of Alopecia Areata, a chronic autoimmune disorder characterized by patchy hair loss. The drug is now available to patients in the U.S. after receiving regulatory approval, and it can be prescribed by physicians for individuals suffering from the more advanced forms of the condition.
According to Sun Pharma’s official press release, Leqselvi is a Janus kinase (JAK) inhibitor and represents an important therapeutic option for patients who previously had limited treatment choices.
The U.S. FDA approved deuruxolitinib for Alopecia Areata based on clinical trials demonstrating significant hair regrowth in a majority of patients over a 24-week period. Sun Pharma holds the exclusive rights to market the drug in the U.S. under the terms of its agreement with Incyte.
